Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)

    Summary
    EudraCT number
    2018-004280-32
    Trial protocol
    GB   DK   IE   PT   ES   NL   BE   HU   PL   GR   IT  
    Global end of trial date
    11 May 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    26 May 2024
    First version publication date
    26 May 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AG10-301
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03860935
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Eidos Therapeutics, Inc.
    Sponsor organisation address
    1800 Owens St., Ste C-1200, San Francisco, CA 94158, United States,
    Public contact
    VP, Clinical Operations , Eidos Therapeutics Inc., a BridgeBio Company, 001 415-887-1471, Mark.McGovern@bridgebio.com
    Scientific contact
    VP, Clinical Development , Eidos Therapeutics Inc., a BridgeBio Company, 001 415-887-1471, JF.Tamby@bridgebio.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 Nov 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    11 May 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine the efficacy of acoramidis in the treatment of participants with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) by evaluating the difference between the acoramidis and placebo groups in the combined endpoints of All-Cause Mortality, the cumulative frequency of cardiovascular (CV)-related hospitalization, change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP), and change from baseline in 6-Minute Walk Test (6MWT).
    Protection of trial subjects
    This study was conducted in compliance with the protocol and in accordance with the ICH GCP guidelines, US Title 21 CFR Parts 11, 50, 54, 56, and 312; the EU Clinical Trials Directive (and Clinical Trial Regulation when in effect); principles enunciated in the Declaration of Helsinki; and all human clinical research regulations of the countries where the study was conducted.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    25 Apr 2019
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 126
    Country: Number of subjects enrolled
    Australia: 71
    Country: Number of subjects enrolled
    Canada: 32
    Country: Number of subjects enrolled
    New Zealand: 28
    Country: Number of subjects enrolled
    Israel: 20
    Country: Number of subjects enrolled
    Brazil: 7
    Country: Number of subjects enrolled
    Korea, Republic of: 4
    Country: Number of subjects enrolled
    Netherlands: 16
    Country: Number of subjects enrolled
    Poland: 2
    Country: Number of subjects enrolled
    Portugal: 2
    Country: Number of subjects enrolled
    Spain: 58
    Country: Number of subjects enrolled
    United Kingdom: 86
    Country: Number of subjects enrolled
    Belgium: 27
    Country: Number of subjects enrolled
    Czechia: 28
    Country: Number of subjects enrolled
    Denmark: 43
    Country: Number of subjects enrolled
    Greece: 8
    Country: Number of subjects enrolled
    Ireland: 6
    Country: Number of subjects enrolled
    Italy: 68
    Worldwide total number of subjects
    632
    EEA total number of subjects
    258
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    21
    From 65 to 84 years
    544
    85 years and over
    67

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Subjects were enrolled from 95 centers in 18 countries between April 2019 and May 2023.

    Pre-assignment
    Screening details
    The study included a Screening Period of up to 35 days, a fixed treatment duration of 30 months, and a 1-month follow-up after the last dose of study drug.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Acoramidis HCl 800 mg
    Arm description
    Participants with symptomatic ATTR-CM received 800 mg acoramidis HCl BID (two 400 mg acoramidis HCl tablets, each equivalent to 356 mg acoramidis [active moiety])
    Arm type
    Experimental

    Investigational medicinal product name
    Acoramidis
    Investigational medicinal product code
    Other name
    AG10
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Administered orally BID.

    Arm title
    Placebo
    Arm description
    Participants with symptomatic ATTR-CM received matching placebo (two matching placebo tablets BID)
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Administered orally BID.

    Number of subjects in period 1
    Acoramidis HCl 800 mg Placebo
    Started
    421
    211
    Completed
    331
    154
    Not completed
    90
    57
         Consent withdrawn by subject
    15
    6
         Death
    75
    51

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Acoramidis HCl 800 mg
    Reporting group description
    Participants with symptomatic ATTR-CM received 800 mg acoramidis HCl BID (two 400 mg acoramidis HCl tablets, each equivalent to 356 mg acoramidis [active moiety])

    Reporting group title
    Placebo
    Reporting group description
    Participants with symptomatic ATTR-CM received matching placebo (two matching placebo tablets BID)

    Reporting group values
    Acoramidis HCl 800 mg Placebo Total
    Number of subjects
    421 211 632
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    12 9 21
        Adults (65-77)
    190 95 285
        Adults (≥78)
    219 107 326
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    77.37 ( 6.450 ) 77.09 ( 6.763 ) -
    Gender categorical
    Units: Subjects
        Female
    37 25 62
        Male
    384 186 570
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    8 4 12
        Not Hispanic or Latino
    401 199 600
        Unknown or Not Reported
    12 8 20
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 1 1
        Asian
    10 3 13
        Native Hawaiian or Other Pacific Islander
    0 1 1
        Black or African American
    20 10 30
        White
    368 187 555
        More than one race
    2 0 2
        Unknown or Not Reported
    21 9 30

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Acoramidis HCl 800 mg
    Reporting group description
    Participants with symptomatic ATTR-CM received 800 mg acoramidis HCl BID (two 400 mg acoramidis HCl tablets, each equivalent to 356 mg acoramidis [active moiety])

    Reporting group title
    Placebo
    Reporting group description
    Participants with symptomatic ATTR-CM received matching placebo (two matching placebo tablets BID)

    Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.

    Close Top of page
    End point title
    A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.
    End point description
    The Finkelstein-Schoenfeld method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. It compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study. The mITT population is a subset of ITT subjects which includes all randomized subjects who received at least 1 dose of IMP & have at least 1 post baseline efficacy assessment as well as a baseline eGFR >= 30 mL/min/1.73 m^2.
    End point type
    Primary
    End point timeframe
    Baseline up to Month 30
    End point values
    Acoramidis HCl 800 mg Placebo
    Number of subjects analysed
    409
    202
    Units: Percent of Wins from Win Ratio
        number (not applicable)
    63.7
    35.9
    Statistical analysis title
    Finkelstein-Schoenfeld (F-S) Analysis
    Statistical analysis description
    Finkelstein-Schoenfeld (F-S) Analysis for Hierarchical Combination of All-Cause Mortality, cumulative frequency of CV-related Hospitalization, change from baseline in NT-proBNP and change from baseline in 6MWT.
    Comparison groups
    Placebo v Acoramidis HCl 800 mg
    Number of subjects included in analysis
    611
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Finkelstein-Schoenfeld Method
    Confidence interval

    Secondary: Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)

    Close Top of page
    End point title
    Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)
    End point description
    6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. The mITT population is a subset of ITT subjects which includes all randomized subjects who received at least 1 dose of IMP & have at least 1 post baseline efficacy assessment as well as a baseline eGFR >= 30 mL/min/1.73 m^2.
    End point type
    Secondary
    End point timeframe
    Month 30
    End point values
    Acoramidis HCl 800 mg Placebo
    Number of subjects analysed
    407
    202
    Units: Meter
        least squares mean (standard error)
    -64.65 ( 5.508 )
    -104.29 ( 7.772 )
    Statistical analysis title
    Mixed Effects Model with Repeated Measures
    Statistical analysis description
    LS means are from a MMRM model with treatment group, visit, randomization stratification factors of genotype, NT-proBNP level and eGFR level (as recorded in IXRS) and treatment group-by-visit interaction as factors, and baseline value as covariate. Missing measurements due to early discontinuation of study treatment and due to death were imputed using the Jump to Reference (J2R) method and sampling with replacement from the worst 5% of observed values, respectively, as specified in study SAP.
    Comparison groups
    Acoramidis HCl 800 mg v Placebo
    Number of subjects included in analysis
    609
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Least Squares Mean Difference
    Point estimate
    39.64
    Confidence interval
         level
    96%
         sides
    2-sided
         lower limit
    20.18
         upper limit
    59.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    9.477

    Secondary: Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)

    Close Top of page
    End point title
    Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
    End point description
    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status. The mITT population is a subset of ITT subjects which includes all randomized subjects who received at least 1 dose of IMP & have at least 1 post baseline efficacy assessment as well as a baseline eGFR >= 30 mL/min/1.73 m^2.
    End point type
    Secondary
    End point timeframe
    Month 30
    End point values
    Acoramidis HCl 800 mg Placebo
    Number of subjects analysed
    408
    202
    Units: Score on a scale
        least squares mean (standard error)
    -11.48 ( 1.181 )
    -21.42 ( 1.651 )
    Statistical analysis title
    Mixed Effects Model with Repeated Measures
    Statistical analysis description
    LS means are from a MMRM model with treatment group, visit, randomization stratification factors of genotype, NT-proBNP level and eGFR level (as recorded in IXRS) and treatment group-by-visit interaction as factors, and baseline value as covariate. Missing measurements due to early discontinuation of study treatment and due to death were imputed using the Jump to Reference (J2R) method and sampling with replacement from the worst 5% of observed values, respectively, as specified in study SAP.
    Comparison groups
    Acoramidis HCl 800 mg v Placebo
    Number of subjects included in analysis
    610
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    Least Squares Mean Difference
    Point estimate
    9.94
    Confidence interval
         level
    96%
         sides
    2-sided
         lower limit
    5.79
         upper limit
    14.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    2.024

    Secondary: Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level

    Close Top of page
    End point title
    Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level
    End point description
    Serum TTR (Prealbumin) is an in vivo biomarker of stabilization. The mITT population is a subset of ITT subjects which includes all randomized subjects who received at least 1 dose of IMP & have at least 1 post baseline efficacy assessment as well as a baseline eGFR >= 30 mL/min/1.73 m^2.
    End point type
    Secondary
    End point timeframe
    Month 30
    End point values
    Acoramidis HCl 800 mg Placebo
    Number of subjects analysed
    406
    199
    Units: mg/dL
        least squares mean (standard error)
    5.78 ( 0.391 )
    -1.32 ( 0.541 )
    Statistical analysis title
    Mixed Effects Model with Repeated Measures
    Statistical analysis description
    LS means are from a MMRM model with treatment group, visit, randomization stratification factors of genotype, NT-proBNP level and eGFR level (as recorded in IXRS) and treatment group-by-visit interaction as factors, and baseline value as covariate. Missing measurements due to early discontinuation of study treatment and due to death were imputed using the Jump to Reference (J2R) method and sampling with replacement from the worst 5% of observed values, respectively, as specified in study SAP.
    Comparison groups
    Acoramidis HCl 800 mg v Placebo
    Number of subjects included in analysis
    605
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    LS Mean Difference
    Point estimate
    7.1
    Confidence interval
         level
    96%
         sides
    2-sided
         lower limit
    5.73
         upper limit
    8.46
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.665

    Secondary: All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)

    Close Top of page
    End point title
    All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)
    End point description
    Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death. The mITT population is a subset of ITT subjects which includes all randomized subjects who received at least 1 dose of IMP & have at least 1 post baseline efficacy assessment as well as a baseline eGFR >= 30 mL/min/1.73 m^2.
    End point type
    Secondary
    End point timeframe
    Baseline up to Month 30
    End point values
    Acoramidis HCl 800 mg Placebo
    Number of subjects analysed
    409
    202
    Units: Participants
    79
    52
    Statistical analysis title
    Cochran-Mantel-Haenszel Test
    Comparison groups
    Acoramidis HCl 800 mg v Placebo
    Number of subjects included in analysis
    611
    Analysis specification
    Pre-specified
    Analysis type
    superiority [1]
    P-value
    = 0.0569
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Notes
    [1] - Cochran-Mantel-Haenszel test is stratified by randomization stratification factors of genotype, NT-proBNP level and eGFR level as recorded in IXRS.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment emergent adverse events (TEAEs) are events (a) with onset after first dose of study drug, or (b) present before first dose but increased in severity after, and (c) with onset <= 30 days after last dose or until first dose in extension study.
    Adverse event reporting additional description
    TEAEs are any untoward or unfavorable medical occurrence in a participant, whether or not considered related to the participant's participation in the research, with event onset dates or increase in severity date as defined in the Time Frame Section above.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    24.1
    Reporting groups
    Reporting group title
    Acoramidis HCl 800 mg
    Reporting group description
    Participants with symptomatic ATTR-CM received 800 mg acoramidis HCl BID (two 400 mg acoramidis HCl tablets, each equivalent to 356 mg acoramidis [active moiety]. Number of deaths (all causes) is based upon 30 months. Number of deaths resulting from adverse events is referent to the TEAE timeframe only.

    Reporting group title
    Placebo
    Reporting group description
    Participants with symptomatic ATTR-CM received matching placebo BID, orally (two matching placebo tablets, BID). Number of deaths (all causes) is based upon 30 months. Number of deaths resulting from adverse events is referent to the TEAE timeframe only.

    Serious adverse events
    Acoramidis HCl 800 mg Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    230 / 421 (54.63%)
    137 / 211 (64.93%)
         number of deaths (all causes)
    84
    55
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adenocarcinoma pancreas
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Basal cell carcinoma
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder cancer
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bladder cancer recurrent
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Chronic lymphocytic leukaemia
         subjects affected / exposed
    0 / 421 (0.00%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colorectal cancer
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diffuse large B-cell lymphoma
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal cancer metastatic
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Lung adenocarcinoma recurrent
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung cancer metastatic
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant pleural effusion
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Medullary thyroid cancer
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metastases to liver
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myelodysplastic syndrome
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Prostate cancer metastatic
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal cell carcinoma
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestine adenocarcinoma
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tonsil cancer
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tonsil cancer metastatic
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Transitional cell carcinoma
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Varicose vein ruptured
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic stenosis
         subjects affected / exposed
    3 / 421 (0.71%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femoral artery embolism
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lymphoedema
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Orthostatic hypotension
         subjects affected / exposed
    3 / 421 (0.71%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral vascular disorder
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombosis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Surgical and medical procedures
    Euthanasia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    1 / 421 (0.24%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Complication associated with device
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cyst
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    3 / 421 (0.71%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 3
    0 / 1
    Disease progression
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Fatigue
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Non-cardiac chest pain
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral swelling
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sudden death
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Immune system disorders
    Amyloidosis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    0 / 421 (0.00%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Prostatitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Acute pulmonary oedema
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Choking
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    2 / 421 (0.48%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspnoea exertional
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haemoptysis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    2 / 421 (0.48%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleurisy
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary congestion
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 421 (0.00%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Psychiatric disorders
    Bipolar disorder
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Delirium
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Insomnia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Product issues
    Device dislocation
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device failure
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device loosening
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device malfunction
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lead dislodgement
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac output decreased
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Electrocardiogram QT prolonged
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    International normalised ratio increased
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oxygen saturation decreased
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    SARS-CoV-2 test positive
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Troponin T increased
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Troponin increased
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Back injury
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bone contusion
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cervical vertebral fracture
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Concussion
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cystitis radiation
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eschar
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    13 / 421 (3.09%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 13
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Femoral neck fracture
         subjects affected / exposed
    4 / 421 (0.95%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fractured coccyx
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Fractured sacrum
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematuria traumatic
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intentional overdose
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ligament sprain
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Limb injury
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Medication error
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Meniscus injury
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pelvic fracture
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Periprosthetic fracture
         subjects affected / exposed
    1 / 421 (0.24%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haematoma
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haematuria
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Procedural pain
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    5 / 421 (1.19%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin laceration
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdural haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Traumatic haemothorax
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Traumatic intracranial haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Urinary retention postoperative
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    5 / 421 (1.19%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aortic valve stenosis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    19 / 421 (4.51%)
    15 / 211 (7.11%)
         occurrences causally related to treatment / all
    0 / 19
    0 / 18
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial flutter
         subjects affected / exposed
    3 / 421 (0.71%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial tachycardia
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrial thrombosis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrioventricular block
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    8 / 421 (1.90%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Bifascicular block
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bradyarrhythmia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bundle branch block
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure
         subjects affected / exposed
    45 / 421 (10.69%)
    39 / 211 (18.48%)
         occurrences causally related to treatment / all
    0 / 64
    0 / 77
         deaths causally related to treatment / all
    0 / 18
    0 / 8
    Cardiac amyloidosis
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    0 / 2
    Cardiac arrest
         subjects affected / exposed
    4 / 421 (0.95%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 4
         deaths causally related to treatment / all
    0 / 2
    0 / 3
    Cardiac failure acute
         subjects affected / exposed
    21 / 421 (4.99%)
    14 / 211 (6.64%)
         occurrences causally related to treatment / all
    1 / 28
    0 / 19
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    Cardiac failure chronic
         subjects affected / exposed
    6 / 421 (1.43%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 4
         deaths causally related to treatment / all
    0 / 5
    0 / 2
    Cardiac failure congestive
         subjects affected / exposed
    5 / 421 (1.19%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 3
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    Cardiac flutter
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac tamponade
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Cardiogenic shock
         subjects affected / exposed
    1 / 421 (0.24%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 5
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cardiorenal syndrome
         subjects affected / exposed
    3 / 421 (0.71%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    Chronic left ventricular failure
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mitral valve incompetence
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Myocardial ischaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Palpitations
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pericarditis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Right ventricular failure
         subjects affected / exposed
    1 / 421 (0.24%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 2
    Sinus node dysfunction
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Trifascicular block
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    6 / 421 (1.43%)
    5 / 211 (2.37%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute left ventricular failure
         subjects affected / exposed
    3 / 421 (0.71%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ventricular fibrillation
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Nervous system disorders
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    3 / 421 (0.71%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Cervical radiculopathy
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chorea
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cranial nerve paralysis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dementia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dizziness postural
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dysarthria
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Embolic stroke
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic encephalopathy
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neuropathy peripheral
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Parkinson's disease
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Presyncope
         subjects affected / exposed
    5 / 421 (1.19%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Restless legs syndrome
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subarachnoid haemorrhage
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Syncope
         subjects affected / exposed
    6 / 421 (1.43%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    7 / 421 (1.66%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 9
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune thrombocytopenia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Iron deficiency anaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Normochromic normocytic anaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Conjunctival haemorrhage
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Macular hole
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinal artery occlusion
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    3 / 421 (0.71%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diverticulum intestinal haemorrhagic
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Duodenitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gingival bleeding
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematochezia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hiatus hernia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    6 / 421 (1.43%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Inguinal hernia strangulated
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal ischaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Intestinal metaplasia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Intestinal perforation
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mallory-Weiss syndrome
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Mechanical ileus
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Melaena
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    2 / 421 (0.48%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    4 / 421 (0.95%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Bile duct stone
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Biliary colic
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Hepatic function abnormal
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ischaemic hepatitis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Angioedema
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug eruption
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eczema asteatotic
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Purpura senile
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin ulcer
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Telangiectasia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    21 / 421 (4.99%)
    8 / 211 (3.79%)
         occurrences causally related to treatment / all
    0 / 21
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Calculus bladder
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Chronic kidney disease
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    End stage renal disease
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    Haematuria
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nephropathy toxic
         subjects affected / exposed
    1 / 421 (0.24%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Prerenal failure
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal impairment
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Arthritis
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bursitis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lumbar spinal stenosis
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 421 (0.24%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    3 / 421 (0.71%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal osteoarthritis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal stenosis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Synovial cyst
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tenosynovitis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Cellulitis
         subjects affected / exposed
    7 / 421 (1.66%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 7
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal sepsis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Abscess limb
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bacterial sepsis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    9 / 421 (2.14%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 9
    0 / 4
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    2 / 421 (0.48%)
    8 / 211 (3.79%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    Cholecystitis infective
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cystitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related sepsis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Escherichia bacteraemia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Haematoma infection
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Implant site infection
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infective exacerbation of bronchiectasis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infective tenosynovitis
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intervertebral discitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    3 / 421 (0.71%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lung abscess
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Orchitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    12 / 421 (2.85%)
    6 / 211 (2.84%)
         occurrences causally related to treatment / all
    0 / 13
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia staphylococcal
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural infection
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retroperitoneal abscess
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    4 / 421 (0.95%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Sepsis pasteurella
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic arthritis streptococcal
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    4 / 421 (0.95%)
    4 / 211 (1.90%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 3
    0 / 0
    Sinusitis
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin graft infection
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin infection
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal bacteraemia
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    0 / 421 (0.00%)
    2 / 211 (0.95%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    2 / 421 (0.48%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    7 / 421 (1.66%)
    3 / 211 (1.42%)
         occurrences causally related to treatment / all
    0 / 8
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection bacterial
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection pseudomonal
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    2 / 421 (0.48%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Cachexia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Dehydration
         subjects affected / exposed
    4 / 421 (0.95%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gout
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperkalaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypervolaemia
         subjects affected / exposed
    3 / 421 (0.71%)
    5 / 211 (2.37%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypocalcaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    0 / 211 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    1 / 421 (0.24%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 421 (0.00%)
    1 / 211 (0.47%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Acoramidis HCl 800 mg Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    410 / 421 (97.39%)
    199 / 211 (94.31%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Basal cell carcinoma
         subjects affected / exposed
    15 / 421 (3.56%)
    12 / 211 (5.69%)
         occurrences all number
    15
    12
    Vascular disorders
    Hypotension
         subjects affected / exposed
    30 / 421 (7.13%)
    14 / 211 (6.64%)
         occurrences all number
    33
    14
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    21 / 421 (4.99%)
    8 / 211 (3.79%)
         occurrences all number
    22
    8
    Fatigue
         subjects affected / exposed
    42 / 421 (9.98%)
    26 / 211 (12.32%)
         occurrences all number
    47
    28
    Oedema peripheral
         subjects affected / exposed
    33 / 421 (7.84%)
    25 / 211 (11.85%)
         occurrences all number
    36
    28
    Peripheral swelling
         subjects affected / exposed
    6 / 421 (1.43%)
    14 / 211 (6.64%)
         occurrences all number
    6
    15
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    32 / 421 (7.60%)
    18 / 211 (8.53%)
         occurrences all number
    37
    20
    Dyspnoea
         subjects affected / exposed
    51 / 421 (12.11%)
    37 / 211 (17.54%)
         occurrences all number
    60
    53
    Epistaxis
         subjects affected / exposed
    21 / 421 (4.99%)
    7 / 211 (3.32%)
         occurrences all number
    24
    7
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    20 / 421 (4.75%)
    15 / 211 (7.11%)
         occurrences all number
    21
    15
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    26 / 421 (6.18%)
    4 / 211 (1.90%)
         occurrences all number
    29
    5
    Weight decreased
         subjects affected / exposed
    16 / 421 (3.80%)
    13 / 211 (6.16%)
         occurrences all number
    17
    13
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    59 / 421 (14.01%)
    38 / 211 (18.01%)
         occurrences all number
    83
    60
    Skin laceration
         subjects affected / exposed
    11 / 421 (2.61%)
    11 / 211 (5.21%)
         occurrences all number
    15
    13
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    55 / 421 (13.06%)
    36 / 211 (17.06%)
         occurrences all number
    58
    41
    Cardiac failure
         subjects affected / exposed
    69 / 421 (16.39%)
    61 / 211 (28.91%)
         occurrences all number
    103
    89
    Ventricular tachycardia
         subjects affected / exposed
    12 / 421 (2.85%)
    12 / 211 (5.69%)
         occurrences all number
    14
    13
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    45 / 421 (10.69%)
    22 / 211 (10.43%)
         occurrences all number
    54
    23
    Syncope
         subjects affected / exposed
    15 / 421 (3.56%)
    12 / 211 (5.69%)
         occurrences all number
    17
    17
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    33 / 421 (7.84%)
    15 / 211 (7.11%)
         occurrences all number
    36
    15
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    22 / 421 (5.23%)
    3 / 211 (1.42%)
         occurrences all number
    22
    5
    Constipation
         subjects affected / exposed
    51 / 421 (12.11%)
    31 / 211 (14.69%)
         occurrences all number
    55
    36
    Diarrhoea
         subjects affected / exposed
    48 / 421 (11.40%)
    16 / 211 (7.58%)
         occurrences all number
    55
    17
    Nausea
         subjects affected / exposed
    24 / 421 (5.70%)
    11 / 211 (5.21%)
         occurrences all number
    26
    11
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    25 / 421 (5.94%)
    8 / 211 (3.79%)
         occurrences all number
    27
    11
    Rash
         subjects affected / exposed
    21 / 421 (4.99%)
    11 / 211 (5.21%)
         occurrences all number
    24
    13
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    35 / 421 (8.31%)
    16 / 211 (7.58%)
         occurrences all number
    43
    22
    Haematuria
         subjects affected / exposed
    17 / 421 (4.04%)
    16 / 211 (7.58%)
         occurrences all number
    19
    18
    Renal impairment
         subjects affected / exposed
    35 / 421 (8.31%)
    17 / 211 (8.06%)
         occurrences all number
    39
    17
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    47 / 421 (11.16%)
    22 / 211 (10.43%)
         occurrences all number
    61
    31
    Back pain
         subjects affected / exposed
    38 / 421 (9.03%)
    14 / 211 (6.64%)
         occurrences all number
    42
    15
    Muscle spasms
         subjects affected / exposed
    34 / 421 (8.08%)
    15 / 211 (7.11%)
         occurrences all number
    42
    15
    Pain in extremity
         subjects affected / exposed
    30 / 421 (7.13%)
    11 / 211 (5.21%)
         occurrences all number
    40
    15
    Infections and infestations
    COVID-19
         subjects affected / exposed
    80 / 421 (19.00%)
    27 / 211 (12.80%)
         occurrences all number
    80
    28
    Nasopharyngitis
         subjects affected / exposed
    21 / 421 (4.99%)
    11 / 211 (5.21%)
         occurrences all number
    23
    12
    Upper respiratory tract infection
         subjects affected / exposed
    22 / 421 (5.23%)
    12 / 211 (5.69%)
         occurrences all number
    24
    12
    Urinary tract infection
         subjects affected / exposed
    46 / 421 (10.93%)
    26 / 211 (12.32%)
         occurrences all number
    54
    31
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    19 / 421 (4.51%)
    11 / 211 (5.21%)
         occurrences all number
    21
    11
    Gout
         subjects affected / exposed
    46 / 421 (10.93%)
    17 / 211 (8.06%)
         occurrences all number
    66
    23
    Hypervolaemia
         subjects affected / exposed
    21 / 421 (4.99%)
    17 / 211 (8.06%)
         occurrences all number
    30
    19
    Hypokalaemia
         subjects affected / exposed
    21 / 421 (4.99%)
    11 / 211 (5.21%)
         occurrences all number
    25
    17

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    19 Apr 2019
    − Clarified contraception requirements and acceptable methods. − Circulatory biomarkers: changes in NT-proBNP and TnI between baseline and Month 30. − Change from baseline after 30 months of treatment in EQ-5D-5L.
    28 Aug 2019
    − Circulatory biomarkers and EQ-5D-5L: change from baseline in NT-proBNP, TnI, and EQ-5D-5L (to allow for analysis after the study). − Following approval of tafamidis in some regions, clarified the ability to use tafamidis after at least 24 months of double-blind treatment. − Clarified that participants may withdraw from the study at any time. − Immunoelectron microscopy added as a diagnostic method to Screening criteria in order to assist with confirmation of the diagnosis of ATTR-CM in patients with concurrent MGUS. − Clarified requirement for immunofixation of serum and urine. − The requirement of confirmation of diagnosis of ATTR-CM by central review of clinical data was deleted from the eligibility criteria but a clarification on the timeframe for confirmation of diagnosis by central review was added. − Clarified that the two 6MWTs did not need to be consecutive and that a third test (if needed) should be repeated within 24 hours to 1 week. − Transient ischemic attack was added as an exclusionary condition. − Revised threshold to allow for risk/benefit assessments at higher levels of NT-proBNP. − Changed blanket exclusionary concomitant medications of calcium channel blockers and digitalis to exclusion of calcium channel blockers for those with conduction system effects, to allow use of dihydropyridine calcium channel blockers, and to allow use of digoxin if required for management of atrial fibrillation with rapid ventricular response. − Removed the use of study drug dosing diaries. − Removed requirement to assess vital signs postdose. − Changed the per-protocol population to include all participants from the mITT set who did not have major protocol violations or deviations. − Secondary endpoint analyses changed to include Cox regression model adjusting for stratification factors. − Definition of CV-related hospitalization was clarified.
    13 Feb 2020
    − Increased number of study centers. − Immunohistochemistry was added as a diagnostic method to the Screening criteria in order to assist with confirmation of the diagnosis of ATTR-CM in patients with concurrent MGUS. − Deleted text on adjustment of study drug dose to 400 mg. − Clarified ability to use tafamidis after at least 12 months of double-blind treatment. The change from 24 months to 12 months was made to decrease the potential that participants may discontinue from the study in order to access tafamidis. This change was based on the feedback from the study Steering Committee and Principal Investigators in light of approval of tafamidis for ATTR-CM in some participating countries [eg, USA approval: May 2019; EU: February 2020 (Maurer et al., 2018; Vyndaqel-EPAR, 2019)].
    14 Jan 2021
    − Added guidance on some study procedures. − Added that EOCIs adjudicated by CEC as not CV-related were to be considered AEs. − Added that EOCIs were considered part of efficacy endpoint of CV-related hospitalizations.
    31 Mar 2021
    − Revised the F-S test of the primary endpoint to reflect the addition of change from baseline in 6MWD: a hierarchical combination of all-cause mortality, cumulative frequency of CV-related hospitalization, and change from baseline in 6MWD over a 30-month fixed treatment duration. − OLE was removed as separate OLE study. − Clarified elements of PK-PD substudy and added PopPK analysis and PK-PD relationship as exploratory endpoints. − Updated statistical plan for control of α. − Added guidance on some study procedures.
    16 Jun 2022
    − Revised the F-S test of the primary endpoint to reflect addition of NT-proBNP: a hierarchical combination of all-cause mortality, cumulative frequency of CV-related hospitalization, change from baseline in NT-proBNP, and change from baseline in 6MWD over a 30-month fixed treatment duration. − Promoted two secondary objectives/endpoints to key secondary objectives/endpoints: 1) change from baseline to Month 30 in serum TTR (prealbumin) level (an in vivo measure of TTR stabilization); 2) all-cause mortality by Month 30 including death due to any cause, heart transplant, or CMAD. − Revised secondary objectives and associated endpoints: 1) moved key primary endpoint “A hierarchical combination of all-cause mortality, cumulative frequency of CV-related hospitalization, and change from baseline in 6MWD over a 30-month fixed treatment duration” and the associated objective to the secondary endpoint/objective section; 2) promoted exploratory endpoint “Change in NT-proBNP from baseline to Month 30 of treatment” and associated objective to secondary objective/endpoint section. − Clarified discontinuation of participants from therapy or withdrawal from the study. − Clarified Investigator-responsibilities for collection and documentation of potential study endpoints, with particular reference to adjudicated events. − Added definition of CMAD. − Added text clarifying that an independent CEC was to review and adjudicate “heart transplant, CMAD” to determine whether they met the definition of protocol-specified efficacy endpoints. − Added guidance on some study procedures.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 15:35:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA